Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group

Página do item simplificado
dc.citation.issue4
dc.citation.volumev. 102
dc.contributor.authorChhablani, Jay
dc.contributor.authorPaulose, Remya Mareen
dc.contributor.authorLasave, Andres F.
dc.contributor.authorWu, Lihteh
dc.contributor.authorCarpentier, Cristian
dc.contributor.authorMaia, Mauricio [UNIFESP]
dc.contributor.authorLujan, Silvio
dc.contributor.authorRojas, Sergio
dc.contributor.authorSerrano, Martin
dc.contributor.authorBerrocal, Maria H.
dc.contributor.authorArevalo, J. Fernando
dc.coverageLondon
dc.date.accessioned2020-07-20T16:31:06Z
dc.date.available2020-07-20T16:31:06Z
dc.date.issued2018
dc.description.abstractPurpose To report the long-term anatomical and visual outcomes of intravitreal bevacizumab (IVB) monotherapy in naive choroidal neovascularisation (CNV) caused by myopia. Methods Retrospective analysis of naive CNV secondary to myopia that underwent antivascular endothelial growth factor monotherapy was performed. Collected data included demographic details, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were resolution of CNV activity at the last visit. Secondary outcomes included change in visual acuity, number of injections and adverse events. Results Thirty-three eyes of 31 subjects with a mean age of 51.4816.4 years were included. The mean follow-up was 66.47 months. 27 eyes had type 2 CNV and the rest seven eyes had type 1 CNV. The mean number of IVB injections per eye was 4.9. Mean visual acuity at baseline reduced from 0.65 +/- 0.33logMAR units (Snellen equivalent=20/89) to 0.73 +/- 0.50logMAR units (20/107) at final follow-up (p=0.003). The mean central macular thickness decreased from 309.31 +/- 86 mu m at baseline to 267.5 +/- 70.89 mu m at the last visit (p=0.03). However, visual acuity was maintained (+/- 1line of baseline) in 13 eyes (39.4%), 2line improvement in nine (27.3%) eyes and more than two lines worsening in 11 eyes (33.3%). Foveal atrophy was observed at baseline and last visit in 6 (12.5%) and 14 (29.1%), respectively (p=0.007). No systemic adverse events were observed. Conclusion IVB monotherapy is safe and effective for long-term treatment of CNV secondary to myopia in real life.en
dc.description.affiliationLV Prasad Eye Inst, Hyderabad, Andhra Pradesh, India
dc.description.affiliationClin Privada Ojos, Retina & Vitreous Serv, Mar Del Plata, Buenos Aires, Argentina
dc.description.affiliationInst Cirugia Ocular, San Jose, Costa Rica
dc.description.affiliationLos Andes Univ, Fdn Oftalmol Los Andes, Santiago, Chile
dc.description.affiliationFed Univ Sao Paulo UNIFESP, Retina Div, Dept Ophthalmol & Visual Sci, Sao Paulo, Brazil
dc.description.affiliationMACULA D&T Diagnost Tratamiento & Rehabil Visual, Lima, Peru
dc.description.affiliationFdn Hosp Nuestra Senora Luz, Mexico City, DF, Mexico
dc.description.affiliationCtr Caracas, Clin Oftalmol, Caracas, Venezuela
dc.description.affiliationArevalo Coutinho Fdn Res Ophthalmol, Caracas, Venezuela
dc.description.affiliationUniv Puerto Rico, Dept Ophthalmol, San Juan, PR 00936 USA
dc.description.affiliationJohns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA
dc.description.affiliationUnifespFed Univ Sao Paulo UNIFESP, Retina Div, Dept Ophthalmol & Visual Sci, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent455-459
dc.identifierhttp://dx.doi.org/10.1136/bjophthalmol-2017-310411
dc.identifier.citationBritish Journal Of Ophthalmology. London, v. 102, n. 4, p. 455-459, 2018.
dc.identifier.doi10.1136/bjophthalmol-2017-310411
dc.identifier.issn0007-1161
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/55707
dc.identifier.wosWOS:000429732500007
dc.language.isoeng
dc.publisherBmj Publishing Group
dc.relation.ispartofBritish Journal Of Ophthalmology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectchoroidal neovascularizationen
dc.subjectanti-VEGFen
dc.subjectmyopiaen
dc.subjectbevacizumaben
dc.titleIntravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Groupen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos